Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $16.0852W HIGH $45.42
Volume
1.76 M
Value Traded
47.40 M
Short % Float
20.34%
-9.99%Week
-21.91%1 Month
-23.8%3 Month
+23.51%6 Month
+120.32%5 Year
+243.22%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.25 B
EPS (TTM)
-2.61
P/E Ratio
-
Ent. Value
5.45 B
Total Shares
206.36 M
Float Shares
84.83 M
Insiders
58.93%
Institutions
52.25%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
IMVT Catalyst Timeline
Dated clinical, regulatory and corporate events for Immunovant, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Immunovant, Inc.
247Total events
8Upcoming
65Tier-1 (high impact)
2019 to 2028Coverage
Upcoming catalysts 2
Event history 50
▼Topline ReadoutIMVT-1402Clinical Data
Topline results from proof-of-concept study of IMVT-1402 in CLE
cutaneous lupus erythematosussource ↗
▼Primary Endpoint MissedIMVT-1402Clinical Data
IMVT-1402 missed primary endpoint in CLE proof-of-concept study
cutaneous lupus erythematosussource ↗
▲Safety Data UpdateIMVT-1402Clinical Data
IMVT-1402 demonstrated favorable safety and tolerability profile in CLE study
cutaneous lupus erythematosussource ↗
●Quarterly UpdateCorporate
Immunovant reports financial results for quarter ended June 30, 2026
▲Runway Guidance UpdateIMVT-1402Corporate
Cash runway to potential launch of IMVT-1402 in GD
Graves' disease (GD)source ↗
◆Quarterly UpdateCorporate
Report financial results for Q4 and fiscal year ended March 31, 2026, and provide business update
▲Full ResultsIMVT-1402Clinical Data
Preliminary Week 16 results from IMVT-1402 trial in D2T RA: ACR20 72.7%, ACR50 54.5%, ACR70 35.8%
difficult-to-treat rheumatoid arthritissource ↗
▲Enrollment CompleteIMVT-1402Trial
Proof-of-concept trial in CLE fully enrolled
cutaneous lupus erythematosussource ↗
▼Topline ReadoutBatoclimabClinical Data
Phase 3 topline results for batoclimab in TED
thyroid eye diseasesource ↗
▼Primary Endpoint MissedBatoclimabClinical Data
Phase 3 studies missed primary endpoint
thyroid eye diseasesource ↗
▼Topline ReadoutBatoclimabClinical Data
Topline results from two Phase 3 studies of batoclimab in TED: neither met primary endpoint
thyroid eye diseasesource ↗
▼Program DiscontinuationBatoclimabCorporate
Discontinued further development of batoclimab across all indications
◆Trial InitiationIMVT-1402Trial
Anticipates initiating clinical trials in ten indications by March 31, 2026
◆Timing GuidanceIMVT-1402Presentation
Anticipates initiating clinical trials in 10 indications by March 31, 2026
◆Quarterly UpdateCorporate
Immunovant to report Q3 FY2025 financial results and provide business update
◆Topline ReadoutBatoclimabClinical Data
Both batoclimab Phase 3 TED studies topline readout
Thyroid Eye Disease (TED)source ↗
◆Topline ReadoutBatoclimabClinical Data
First batoclimab Phase 3 TED study topline readout
Thyroid Eye Disease (TED)source ↗
▲Enrollment CompleteIMVT-1402Trial
Potentially registrational trial of IMVT-1402 in D2T RA fully enrolled
D2T RAsource ↗
▼Equity OfferingCorporate
Underwritten financing completed with gross proceeds of ~$550 million
◆Quarterly UpdateCorporate
Immunovant to report Q2 2025 financial results and provide business update
◆Topline ReadoutBatoclimabClinical Data
Top-line results from batoclimab pivotal program in TED
thyroid eye disease (TED)source ↗
◆Oral PresentationBatoclimabPresentation
Presentation of six-month off-treatment data in uncontrolled Graves' disease at ATA 2025
Graves' diseasesource ↗
▲Enrollment CompleteBatoclimabTrial
Enrollment completed for proof-of-concept study (25 patients enrolled in treatment period)
Graves' diseasesource ↗
◆Trial InitiationIMVT-1402Trial
Two potentially registrational global trials for IMVT-1402 in Graves' disease currently enrolling
Graves' diseasesource ↗
◆Oral PresentationBatoclimabPresentation
Remission data from batoclimab proof-of-concept study in GD to be reported at ATA Annual Meeting
Graves' diseasesource ↗
◆Trial InitiationIMVT-1402Trial
Plan to initiate potentially registrational trial in SjD
Sjögren's diseasesource ↗
◆Topline ReadoutBatoclimabClinical Data
Expect to report six-month remission data from proof-of-concept GD study
Graves' diseasesource ↗
▲Trial InitiationIMVT-1402Trial
Initiated potentially registrational study of IMVT-1402 in Sjögren's disease
Sjögren's diseasesource ↗
◆Additional DataBatoclimabClinical Data
Additional data from batoclimab proof-of-concept study in GD including 6-month treatment-free remission data
Graves' disease (GD)source ↗
◆Topline ReadoutBatoclimabClinical Data
Topline data from batoclimab TED program
Thyroid Eye Diseasesource ↗
▲IND ClearanceIMVT-1402IND
IND for IMVT-1402 in CLE now active
Cutaneous Lupus Erythematosus (CLE)source ↗
▲Trial InitiationIMVT-1402Trial
Proof-of-concept trial for IMVT-1402 in CLE initiated
Cutaneous Lupus Erythematosus (CLE)source ↗
▲Pipeline PrioritizationCorporate
IMVT-1402 development expanded into Sjögren's Disease and Cutaneous Lupus Erythematosus
◆Management ChangeCorporate
George Migausky stepped down from board; Robert Susman and Jacob Bauer joined
◆Topline ReadoutBatoclimabClinical Data
Top-line results from batoclimab Phase 3 TED trial expected in H2 2025
thyroid eye diseasesource ↗
◆Topline ReadoutBatoclimabClinical Data
Top-line results from batoclimab pivotal MG trial expected by March 31, 2025
Myasthenia Gravissource ↗
◆Trial InitiationIMVT-1402Trial
Initiation of potentially registrational program for IMVT-1402 in CIDP expected after batoclimab data readout
chronic inflammatory demyelinating polyneuropathysource ↗
◆Additional DataBatoclimabClinical Data
Initial data from period 1 of batoclimab CIDP trial expected by March 31, 2025
Chronic inflammatory demyelinating polyneuropathysource ↗
◆Timing GuidanceIMVT-1402Presentation
On track to initiate potentially registrational trials in 4-5 indications by March 31, 2025
◆Oral PresentationPresentation
Investor webcast to review batoclimab Phase 3 MG and Phase 2b CIDP results
▲Topline ReadoutBatoclimabClinical Data
Initial results from Period 1 of Phase 2b study of batoclimab in CIDP
Chronic Inflammatory Demyelinating Polyneuropathysource ↗
Past FDA Catalysts and PDUFA Decisions
How IMVT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-12-31 | Batoclimab | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C40 / 100
Pipeline Score
$788M
Pipeline Value
Richly Valued
Valuation Signal
5
Drugs Scored
0.1x
rNPV / MCap
Top 39%
Small Cap(rank 257 of 658)
Percentile Rank
Immunovant, Inc. carries a moderate pipeline score (40/100), with $1.2B risk-adjusted pipeline value, led by IMVT-1402 in Subacute Cutaneous Lupus Erythematosus (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IMVT-1402 Small moleculeNCT07039916 | Generalized Myasthenia Gravis | Phase 3 | RECRUITING | 231 | Dec 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every IMVT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| IMVT-1402 | cutaneous lupus erythematosus | 2026-09-23 | did not achieve statistical significance on the primary endpointRead More | Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus ErythematosusRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Venker EricDirector, Officer (Chief Executive Officer) | Sell | -3,506 257,075 held | $34.11 | 10/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IMVT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 5.2 % (10.6 %) | 359.91 M | 9.34 M | -18.96% ( -2.19 M) |
IMVT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IMVT ranks across every disease it competes in
Competitive Position is a premium feature
See how IMVT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIMVT News
IMVT▼ -7.4%on this news
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's proof-of-concept study for IMVT-1402 in cutaneous lupus erythematosus did not meet its primary endpoint, leading the company to halt further development in this area. Despite observing positive trends in multiple endpoints and a favorable safety profile, the results did not justify continued investment. The company remains focused on advancing IMVT-1402 in other autoimmune diseases.
Read more →IMVTImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
Immunovant reported its financial results for the quarter ending June 30, 2026, highlighting that all timelines for the IMVT-1402 clinical development remain on track. The company has a robust cash position of $797.8 million, which supports the potential launch of IMVT-1402 in Graves' disease. However, the net loss for the quarter increased to $153.2 million, reflecting higher research and development expenses.
Read more →IMVTImmunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Immunovant, Inc. will announce its financial results for Q1 2026 on August 6, 2026. The announcement will be followed by a live conference call hosted by Roivant Sciences, which will include a business update. Immunovant focuses on developing therapies for autoimmune diseases, leveraging its expertise in anti-FcRn technology.
Read more →IMVT▲ +35.3%on this news
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
Immunovant, Inc. reported positive clinical results for IMVT-1402, showing significant response rates in a trial for difficult-to-treat rheumatoid arthritis. The company is on track for further updates in 2026, including topline data from a cutaneous lupus erythematosus trial. Despite a substantial net loss, Immunovant's cash reserves support ongoing development efforts.
Read more →IMVTImmunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
Immunovant (Nasdaq: IMVT) has announced that it will report its financial results for the fourth quarter and fiscal year ending March 31, 2026, on May 20, 2026. The company will also provide a business update during a conference call scheduled for 8:00 a.m. ET. This event underscores Immunovant's commitment to transparency and engagement with stakeholders.
Read more →IMVTImmunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Immunovant announced that its Phase 3 studies of batoclimab for thyroid eye disease did not meet their primary endpoint. Despite this, patients showed improvement in proptosis after high-dose treatment. The company plans to review the development of batoclimab with its partner HanAll Biopharma and continue advancing its other candidate, IMVT-1402.
Read more →IMVT▲ +12.4%on this news
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
Immunovant reported its financial results for Q3 2025, highlighting a fully enrolled trial for IMVT-1402 with topline data expected in 2026. The company raised $550 million in financing, extending its cash runway. Upcoming data for batoclimab in thyroid eye disease is also anticipated in early 2026. However, the company recorded a slight increase in net loss compared to the previous year.
Read more →IMVTImmunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Immunovant has announced it will report its financial results for Q3 2025 on February 6, 2026. The company will also provide a business update during the conference call. Investors can access the call via registration, and details will be available on the Immunovant website. The company focuses on developing therapies for autoimmune diseases.
Read more →IMVT▲ +5.3%on this news
Immunovant Announces Pricing of $550 Million Common Stock Financing
Immunovant, Inc. has announced the pricing of an underwritten offering of common stock, aiming to raise approximately $550 million. The funds will support the company's operations and capital expenditures, particularly for the anticipated launch of IMVT-1402 for Graves' Disease. The offering is expected to close on December 12, 2025, pending customary conditions.
Read more →IMVTImmunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025
Immunovant reported its financial results for the second quarter ended September 30, 2025, highlighting a strong cash position and promising clinical trial results for its drug IMVT-1402. The company anticipates topline results from several trials in 2026 and 2027. However, it also noted an increase in net loss and R&D expenses compared to the previous year.
Read more →IMVT▲ +13.1%on this news· ran to +31% by day 3
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
Immunovant (Nasdaq: IMVT) announced it will report its financial results for the second quarter ended September 30, 2025, on November 10, 2025, at 8:00 a.m. ET. The company will also provide a business update during this call. Information regarding the conference call can be found on Immunovant’s investor website, where the archived webcast will be accessible post-call. Immunovant focuses on targeted therapies for individuals with autoimmune diseases.
Read more →IMVT▲ +9.3%on this news
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
Immunovant, Inc. has announced promising six-month off-treatment data for batoclimab in uncontrolled Graves' disease patients. The results, to be presented at the 2025 ATA Annual Meeting, suggest the potential for disease modification and strong treatment durability. The company believes these findings could significantly change treatment approaches for Graves' disease if approved by the FDA.
Read more →IMVTImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025
Immunovant, Inc. reported corporate updates and financial results for the quarter ended June 30, 2025, highlighting the initiation of two potentially registrational trials for its therapy IMVT-1402 in Graves' disease and Sjögren's disease. The company maintains a strong cash position of approximately $598.9 million, enabling ongoing clinical trials across multiple indications, with key results expected by 2027. However, Immunovant also reported a net loss of $120.6 million for the quarter, an increase from the previous year, attributed to higher R&D expenses.
Read more →IMVT▲ +5.6%on this news
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
Immunovant, Inc. has made significant strides with its lead candidate IMVT-1402, focusing on rapid clinical execution for six announced indications. The company plans to initiate multiple potentially registrational studies in diseases such as Graves’ disease and Sjögren's disease by summer 2025. Financial results reveal an increased net loss compared to the previous year, primarily driven by higher R&D expenses, despite a strong cash position of $714 million for ongoing operations. Positive data from prior trials reinforces the potential of IMVT-1402 as a leading treatment in autoimmune diseases.
Read more →IMVTImmunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
Immunovant, Inc. has announced a strategic transition with Eric Venker appointed as CEO, succeeding Pete Salzmann. The company is expanding its IMVT-1402 program to include Sjögren's Disease and Cutaneous Lupus Erythematosus, aiming for best-in-class treatment options. This leadership change comes as development activities for previous treatments conclude.
Read more →IMVTImmunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
Immunovant announced positive topline results from its Phase 3 study of batoclimab in Myasthenia Gravis (MG) and initial results from a Phase 2b study in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The studies demonstrated significant improvements in clinical outcomes, with batoclimab achieving its primary endpoint in MG. The company plans to leverage these results to advance its lead asset, IMVT-1402.
Read more →IMVTImmunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
Immunovant, Inc. will host an investor webcast on March 19 at 8:00 AM ET to discuss results from its Phase 3 study of batoclimab in myasthenia gravis and initial findings from its Phase 2b study in chronic inflammatory demyelinating polyneuropathy. The event will feature CEO Pete Salzmann and Roivant's CEO Matt Gline. A replay will be available after the event.
Read more →IMVT▼ -9.6%on this news
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
Immunovant reported its financial results for Q3 2024, highlighting progress in the development of its lead asset, IMVT-1402. The company has cleared six INDs and plans to initiate clinical trials for ten indications by March 2026. Despite a significant net loss of $111.1 million, Immunovant remains optimistic about upcoming data readouts and the potential of IMVT-1402 in treating autoimmune diseases.
Read more →IMVTForward-looking statements 2 This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities la
Immunovant presented forward-looking statements revealing its plans for the development of IMVT-1402 and batoclimab for autoimmune diseases at the J.P. Morgan Healthcare Conference. The company's focus includes initiating pivotal trials, expanding patient indications, and enhancing financial viability through a healthy cash position. However, the company cautioned about inherent risks and uncertainties affecting trial outcomes and regulatory processes. The lead asset IMVT-1402 is positioned to potentially address several autoimmune indications with anticipated milestones next year.
Read more →About Immunovant, Inc.
Headquarters1000 PARK FORTY PLAZA, DURHAM, NC, 27713
BIOPHARMAWATCH ELITE PLUS
Trade the next IMVT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime